Table 1 Demographic and clinical characteristics of the study subjects
From: Stratified distribution of Th17 and Treg cells in patients with multi-stage rheumatoid arthritis
Characteristics | Ea-RA (n = 131) | Ad-RA (n = 117) | Tr-RA (n = 109) | Healthy controls (n = 97) |
|---|---|---|---|---|
Female, n (%) | 82 (62.60%) | 82 (70.08%) | 81 (74.31%) | 67 (69.07%) |
Age, years | 55.12 ± 15.34 | 56.59 ± 12.97 | 57.80 ± 12.13 | 51.30 ± 8.78 |
WBC (109/L) | 6.93 ± 2.13 a* | 6.78 ± 2.19 | 6.89 ± 2.58 a** | 6.16 ± 1.86 |
Hb (g/L) | 117.54 ± 18.64 a* | 123.41 ± 33.23 | 116.49 ± 24.30 a* | 126.37 ± 11.56 |
PLT (109/L) | 266.50 ± 107.03 a*** | 289.47 ± 106.63 a*** | 278.29 ± 98.93 a*** | 190.59 ± 42.07 |
ESR (mm/h) | 49.74 ± 33.21 | 52.00 ± 36.00 | 57.63 ± 37.15 | _ |
DAS-28-ESR | 4.81 ± 3.02 | 4.49 ± 1.36 | 4.74 ± 1.28 | _ |
RF (U/mL) | 178.11 ± 306.95 | 203.57 ± 284.71 | 225.75 ± 371.70 | _ |
Anti-CCP (U/mL) | 498.35 ± 486.01 | 604.92 ± 586.05 | 651.99 ± 550.60 | _ |
Anti-MCV (U/mL) | 422.50 ± 388.21 | 418.83 ± 392.01 | 412.27 ± 388.11 | _ |
ANA n (%) | 60 (45.8%) | 67 (57.3%) | 57 (52.3%) | _ |
Pred (≤ 10 mg/day | - | - | 20/109 | _ |
DMARDs | - | - | 39/109 |